Unknown

Dataset Information

0

A novel compound heterozygous mutation of the AIRE gene in a patient with autoimmune polyendocrine syndrome type 1.


ABSTRACT: Autoimmune polyendocrine syndrome type 1 (APS-1), or autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy is a rare, autosomal recessive autoimmune disease caused by a mutation of the autoimmune regulator (AIRE) gene. The main symptom triad in APS-1 comprises chronic mucocutaneous candidiasis, adrenal insufficiency, and hypoparathyroidism. Various autoimmune diseases and ectodermal abnormalities are also commonly associated with the syndrome. The treatment of APS-1 includes hormone replacement and symptom control. It is important to monitor such patients for clinical manifestations of their disease through regular follow-up. We report the case of a 10-year-old Korean girl with APS-1 due to a novel compound heterozygous mutation of the AIRE gene. This patient's main clinical manifestations were adrenal insufficiency and chronic mucocutaneous candidiasis. The patient had a previously known pathogenic variant of c.1513delG (p.Ala505ProfsTer16), and a newly discovered variant of c.1360dupC (p.His454ProfsTer50).

SUBMITTER: Suh J 

PROVIDER: S-EPMC6944864 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

A novel compound heterozygous mutation of the AIRE gene in a patient with autoimmune polyendocrine syndrome type 1.

Suh Junghwan J   Choi Han Saem HS   Kwon Ahreum A   Chae Hyun Wook HW   Lee Jin-Sung JS   Kim Ho-Seong HS  

Annals of pediatric endocrinology & metabolism 20191231 4


Autoimmune polyendocrine syndrome type 1 (APS-1), or autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy is a rare, autosomal recessive autoimmune disease caused by a mutation of the autoimmune regulator (AIRE) gene. The main symptom triad in APS-1 comprises chronic mucocutaneous candidiasis, adrenal insufficiency, and hypoparathyroidism. Various autoimmune diseases and ectodermal abnormalities are also commonly associated with the syndrome. The treatment of APS-1 includes hormone rep  ...[more]

Similar Datasets

| S-EPMC4079332 | biostudies-literature
| S-EPMC3540864 | biostudies-literature
| S-EPMC7339480 | biostudies-literature
| S-EPMC5983174 | biostudies-literature
| S-EPMC7440052 | biostudies-literature
2024-02-23 | GSE243061 | GEO
| S-EPMC6348282 | biostudies-literature
| S-EPMC1783420 | biostudies-literature
| S-EPMC5827717 | biostudies-literature
| S-EPMC6059678 | biostudies-literature